Matthew Brougham appointed PHARMAC’s CEO
Media release 16 April 2008
Matthew Brougham appointed PHARMAC’s Chief Executive
Matthew Brougham has been appointed as PHARMAC’s Chief Executive.
The appointment confirms Matthew Brougham in the position he has held in an interim capacity since July 2006.
“I am delighted to confirm the appointment of Matthew Brougham as PHARMAC’s Chief Executive,” PHARMAC Board chairman Richard Waddel says.
Richard Waddel says Matthew Brougham’s more than 10 years’ experience at PHARMAC has given him a sound and detailed understanding of the Government drug-funder’s roles and responsibilities.
“In addition, since taking on the Acting CEO role Matthew has shown the leadership potential we believe is required to take PHARMAC into an era when we are increasingly focussed on improving relationships with our stakeholders.”
Richard Waddel says that, under Matthew Brougham’s leadership, PHARMAC is well placed to respond to the challenges it faces. These include managing access to new medicines, and responding to the actions arising from Medicines New Zealand, the Government’s medicines strategy.
One of PHARMAC’s longest-serving staff, Matthew Brougham joined PHARMAC in 1997, initially as a Therapeutic Group Manager before working as PHARMAC's Senior Analyst, specialising in cost utility analysis, and then becoming manager of the Analysis and Assessment team.
He has an academic background in both economics and science, studying through the University of Tromso (Norway), and Lincoln and Canterbury Universities. Prior to joining PHARMAC, he worked in various sectors including fisheries (fisheries science), transport (policy analysis), social welfare (forecasting and cost modelling), and the Treasury (tax analysis).